Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RM-001 gene-edited autologous CD34+ cell therapy for transfusion-dependent beta-thalassemia
CTR20222947Phase 2Active
- Sponsor
- Reforgene Medicine
- Start
- Apr 2025
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of γ-globin reactivated autologous hematopoietic stem cells in beta thalassemia, sponsored by Reforgene Medicine. Started Apr 2025; status: active.
02
Drugs
γ-globin reactivated autologous hematopoietic stem cells
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on CTR20222947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222947.